Cohort1: Dose escalation phase_dose level 1
|
Administration route |
intravenous|peritoneal infusion |
Dosage |
Low Density Lipoprotein Receptor mRNA Exosomes, 0.044 mg/kg |
Pts |
3 |
Age |
Adult |
|
Cohort2: Dose escalation phase_dose level 2
|
Administration route |
intravenous|peritoneal infusion |
Dosage |
Low Density Lipoprotein Receptor mRNA Exosomes, 0.088 mg/kg |
Pts |
3 |
Age |
Adult |
|
Cohort3: Dose escalation phase_dose level 3
|
Administration route |
intravenous|peritoneal infusion |
Dosage |
Low Density Lipoprotein Receptor mRNA Exosomes, 0.145 mg/kg |
Pts |
3 |
Age |
Adult |
|
Cohort4: Dose escalation phase_dose level 4
|
Administration route |
intravenous|peritoneal infusion |
Dosage |
Low Density Lipoprotein Receptor mRNA Exosomes, 0.220 mg/kg |
Pts |
3 |
Age |
Adult |
|
Cohort5: Dose escalation phase_dose level 5
|
Administration route |
intravenous|peritoneal infusion |
Dosage |
Low Density Lipoprotein Receptor mRNA Exosomes, 0.295 mg/kg |
Pts |
3 |
Age |
Adult |
|
Cohort6: Dose escalation phase_dose level 6
|
Administration route |
intravenous|peritoneal infusion |
Dosage |
Low Density Lipoprotein Receptor mRNA Exosomes, 0.394 mg/kg |
Pts |
3 |
Age |
Adult |
|
Cohort7: Extension phase
|
Administration route |
intravenous|peritoneal infusion |
Pts |
12 |
Age |
Adult |
|